Cognitive impairment in cerebrovascular diseases

Close metadata

Recommended articles:

The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36

Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):55-66

Efficacy of Mexidol in combination with cerebral revascularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74

Traumatic brain injury as risk factor of Alzheimer’s disease and possibilities of pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):45-54

Attention deficit hyperactivity disorder in children and adolescents: lessons from the COVID-19 pandemic. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):60-65

Use of modern classification systems for complex diagnostics of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):121-127

Safety of carotid endarterectomy in patients over 70 years old in early period after ischemic stroke. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(1):82-88

Cerebral amyloid angiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):85-90

Respiratory-syncitial virus: biology, genetic diversity and perspective control preparations. Molecular Genetics, Microbiology and Virology. 2024;(1):16-24

Relapse of primary mediastinal B-cell lymphoma with isolated central nervous system involvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Oncology. 2024;(2):39-45

Cognitive impairment, which is highly prevalent, especially among older people, leads to a decrease in the quality of life of patients, impairment of daily activities, and an increased risk of dementia and mortality. Currently, much attention is paid to mild cognitive impairment. The article discusses diagnostic criteria and possible clinical variants of this syndrome. Given the high rate of progression of mild cognitive impairment to dementia, it is necessary to identify risk groups and carry out therapeutic preventive measures. Correction of potentially modifiable risk factors is considered as a promising direction of therapy. Sufficient physical and mental activity, proper diet, normalization of sleep, visual acuity and hearing are necessary. Preventing stroke and controlling vascular risk factors may reduce the risk of mild cognitive impairment progressing to dementia.

Keywords:

vascular cognitive impairment

dementia

stroke

vascular risk factors

therapy

Prospekta

Authors:

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies

SPIN RSCI: 6775-0279
Scopus AuthorID: 6602240836
ORCID: 0000-0002-6327-3546

Mkhitaryan E.A.

Pirogov Russian National Research Medical University;
Russian Gerontology Research and Clinical Centre — Pirogov Russian National Research Medical University

ORCID: 0000-0002-9054-0881

Levin O.S.

Russian Medical Academy of Continuous Professional Education;
S.P. Botkin City Clinical Hospital

SPIN RSCI: 5342-1373
Scopus AuthorID: 57147160800
ORCID: 0000-0003-3872-5923

Received:

21.02.2024

Accepted:

21.02.2024

List of references:

Chang WE, Chang CH. Vascular Cognitive Impairment and Dementia. Continuum (Minneap Minn). 2022;28(3):750-780. https://doi.org/10.1212/CON.0000000000001124
Boyle PA, Yu L, Wilson RS, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74-83. https://doi.org/10.1002/ana.25123
Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-281. https://doi.org/10.1212/01.WNL.0000149519.47454.F2
Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52(2):195-204. https://doi.org/10.1111/j.1532-5415.2004.52058.x
Zlokovic BV, Gottesman RF, Bernstein KE, et al. Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimer’s & Dementia. 2020;16(12):1714-1733. https://doi.org/10.1002/alz.12157
Toth P, Tarantini S, Csiszar A, et al. Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. Am J Physiol Heart Circ Physiol. 2017;312(1):H1-20. https://doi.org/10.1152/ajpheart.00581.2016
Wen W, Sachdev PS, Li JJ, et al. White matter hyperintensities in the forties: their prevalence and topography in an epidemiological sample aged 44—48. Hum Brain Mapp. 2009;30(4):1155-1167. https://doi.org/10.1002/hbm.20586
de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9-14. https://doi.org/10.1136/jnnp.70.1.9
Dhamoon MS, Cheung Y-K, DeRosa JT, et al. Association between subclinical brain infarcts and functional decline trajectories. J Am Geriatr Soc. 2018;66(11):2144-2150. https://doi.org/10.1111/jgs.15557
Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222. https://doi.org/10.1056/NEJMoa022066
Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41(4):600-606. https://doi.org/10.1161/STROKEAHA.109.570044
Dong C, Nabizadeh N, Caunca M, et al. Cognitive correlates of white matter lesion load and brain atrophy: the Northern Manhattan Study. Neurology. 2015;85(5):441-449. https://doi.org/10.1212/WNL.0000000000001716
Arvanitakis Z, Leurgans SE, Barnes LL, et al. Microinfarct pathology, dementia, and cognitive systems. Stroke. 2011;42(3):722-727. https://doi.org/10.1161/STROKEAHA.110.595082
Cao L, Tan L, Wang H-F, et al. Cerebral microinfarcts and dementia: a systematic review and metaanalysis. Curr Alzheimer Res. 2017;14(7):802-808. https://doi.org/10.2174/1567205013666161201200429
Skrobot OA, O’Brien J, Black S, et al. The Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2017;13(6):624-633. https://doi.org/10.1016/j.jalz.2016.10.007
Pendlebury ST, Cuthbertson FC, Welch SJV, et al. Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke. 2010;41(6):1290-1293. https://doi.org/10.1161/STROKEAHA.110.579888
Erkinjuntti T. Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia. 1994;5(3-4):189-192. https://doi.org/10.1159/000106721
Zhao L, Biesbroek JM, Shi L, et al. Strategic infarct location for post-stroke cognitive impairment: a multivariate lesion-symptom mapping study. J Cereb Blood Flow Metab. 2018;38(8):1299-1311. https://doi.org/10.1177/0271678X17728162
Esin RG, Safina DR, Khakimova AR, et al. Neuroinflammation and neuropathology. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(4):107-112. (In Russ.). https://doi.org/10.17116/jnevro2021121041107
Zaręba-Kozioł M, Burdukiewicz M, Wysłouch-Cieszyńska A. Intracellular Protein S-Nitrosylation-A Cells Response to Extracellular S100B and RAGE Receptor. Biomolecules. 2022;12(5):613. https://doi.org/10.3390/biom12050613
Sorci G, Riuzzi F, Arcuri C, et al. S100B protein in tissue development, repair and regeneration. World J Biol Chem. 2013;4(1):1-12. https://doi.org/10.4331/wjbc.v4.i1.1
Donato R, Sorci G, Riuzzi F, et al. S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008-1022. https://doi.org/10.1016/j.bbamcr.2008.11.009
Baudier J, Gentil BJ. The S100B Protein and Partners in Adipocyte Response to Cold Stress and Adaptive Thermogenesis: Facts, Hypotheses, and Perspectives. Biomolecules. 2020;10(6):843. https://doi.org/10.3390/biom10060843
Ostendorp T, Leclerc E, Galichet A, et al. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 2007;26(16):3868-3878. https://doi.org/10.1038/sj.emboj.7601805
Uspenskaya YuA, Komleva YuK, Pozhilenkova EA, et al. Ligands of RAGE-Proteins: Role in Intercellular Communication and Pathogenesis of Inflammation. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences. 2015;70(6):694-703. (In Russ.). https://doi.org/10.15690/vramn566
Leclerc E, Sturchler E, Vetter SW. The S100B/RAGE Axis in Alzheimer’s Disease. Cardiovasc Psychiatry Neurol. 2010;2010:539581. https://doi.org/10.1155/2010/539581
Bongarzone S, Savickas V, Luzi F, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017;60(17):7213-7232. https://doi.org/10.1021/acs.jmedchem.7b00058
Bianchi R, Kastrisianaki E, Giambanco I, et al. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem. 2011;286(9):7214-7226. https://doi.org/10.1074/jbc.M110.169342
Ghatak S, Dolatabadi N, Gao R, et al. NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. Mol Psychiatry. 2021;26(10):5751-5765. https://doi.org/10.1038/s41380-020-0776-7
Wilder PT, Varney KM, Weber DJ. Targeting S100 Calcium-Binding Proteins with Small Molecule Inhibitors. Methods Mol Biol. 2019;1929:291-310. https://doi.org/10.1007/978-1-4939-9030-6_19
Instructions for the medical use of the drug Prospecta. Date of access: 02/15/2024. (In Russ.). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0c47ac45-d055-4879-b8f3-bf6d2400318f
Belova AN, Bogdanov EI, Voznyuk IA, et al. Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(5):33-39. (In Russ.). https://doi.org/10.17116/jnevro202112105133
Ostroumova OD, Ebzeeva EYu, Polyakova OA, et al. Therapy of asthenia in patients after acute novel coronavirus infection (COVID-19): results of a multicenter, randomized, double-blind, placebocontrolled clinical study. Therapy. 2022;8(8):146-157. (In Russ.). https://doi.org/10.18565/therapy.2022.8.146-157
Tkacheva ON, Mkhitaryan EA, Kolykhalov IV, et al. Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(7):41-49. (In Russ.). https://doi.org/10.17116/jnevro202312307141
Khasanova DR, Yakupova AA, Kamchatnov PR, et al. Therapy of cognitive impairment in patients with cerebral infarction in the internal carotid artery system: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1):24-32. (In Russ.). https://doi.org/10.14412/2074-2711-2024-1-24-32
Levin OS, Kovalchuk VV, Putilina MV, et al. Treatment of mild cognitive impairment of various origins in patients with chronic somatic diseases: results of a multicenter open prospective observational program (PARUS). Effective Pharmacotherapy. Neurology and Psychiatry. 2022;18(43):78-83. (In Russ.).
Shvartsman GI, Skoromets AA, Zhivolupov SA, et al. Therapy of moderate cognitive impairment and asthenia in patients with cerebrovascular pathology: results of a prospective observational study. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(8):82-88. (In Russ.). https://doi.org/10.17116/jnevro202212208188

Close metadata